Pyridine → N-{[6-bromo-1-(4-methoxybenzyl)-3-methyl-2-oxo-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-4-yl]methyl}4-fluorobenzamide

Participants

Reaction Steps

4-(Aminomethyl)-6-bromo-1-(4-methoxybenzyl)-3-methyl-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one (36.8 mg, 0.080 mmol) was dissolved in DMF (1.0 mL), and 4-fluorobenzoic acid (28.1 mg, 0.201 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (46.2 mg, 0.241 mmol), 1-hydroxybenzotriazole monohydride (36.9 mg, 0.241 mmol) and pyridine (0.032 mL, 0.402 mmol) were sequentially added to the reaction solution at room temperature. After the reaction solution was stirred overnight at room temperature, chloroform and water were added thereto and the mixture was stirred at room temperature. The organic layer was separated and washed with saturated brine and then dried over magnesium sulfate. After the drying agent was removed by filtration, the solvent was evaporated under reduced pressure. The residue was purified by thin-layer chromatography (chloroform/methanol=1/10), whereby the objective N-{[6-bromo-1-(4-methoxybenzyl)-3-methyl-2-oxo-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-4-yl]methyl}4-fluorobenzamide (33.9 mg, 73%) was obtained as a white solid.

Provenance & Evidence